Alpine Peaks Capital’s Maravai LifeSciences MRVI Stock Holding History

Alpine Peaks Capital’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-242,000	Closed	-$535K	–	25
2025 Q1	$535K	Buy	242,000 +38,000	+19%	+$150K	0.48%	25
2024 Q4	$1.11M	Sell	204,000 -75,024	-27%	-$483K	0.91%	23
2024 Q3	$2.32M	Sell	279,024 -17,876	-6%	-$155K	1.38%	21
2024 Q2	$2.13M	Sell	296,900 -76,000	-20%	-$656K	1.31%	24
2024 Q1	$3.23M	Sell	372,900 -32,000	-8%	-$216K	1.86%	22
2023 Q4	$2.65M	Buy	404,900 +45,600	+13%	+$295K	1.61%	22
2023 Q3	$3.59M	Buy	359,300 +29,876	+9%	+$328K	2.51%	21
2023 Q2	$4.09M	Buy	329,424 +88,924	+37%	+$1.2M	2.87%	19
2023 Q1	$3.37M	Buy	240,500 +59,000	+33%	+$847K	2.54%	20
2022 Q4	$2.6M	Buy	+181,500	New	+$2.86M	2.1%	22

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

1WCM

12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OAM

Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

Alpine Peaks Capital's MRVI Position: Q2 2025 in Review

Alpine Peaks Capital sold out of Maravai LifeSciences (MRVI) in Q2 2025, closing a stake of 242,000 shares — an estimated $535K sold.

Alpine Peaks Capital first reported a position in MRVI in Q4 2022 and held it in 10 quarters. The position peaked at $4.09M in Q2 2023. 150 funds tracked by Wall St. Rank hold MRVI as of Q2 2025.

Alpine Peaks Capital reported no remaining Maravai LifeSciences position as of Q2 2025 after selling out during the quarter.
Alpine Peaks Capital sold 242,000 Maravai LifeSciences shares in Q2 2025, an estimated $535K.
Alpine Peaks Capital first reported a position in Maravai LifeSciences in Q4 2022 and held it in 10 quarters.
Alpine Peaks Capital's Maravai LifeSciences position peaked at $4.09M in Q2 2023.
150 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2025.

Based on Alpine Peaks Capital's 13F filing for Q2 2025, filed 14 Aug 2025.